Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 136

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 136
---
 partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to office actions within prescribed time limits, non -paymentof fees and failure to properly legalize and submit formal documents. In such an event, its competitors might be able to enter the market, which would have a material adverse effect on its business. NLS may not be able to enforce its intellectual property rights throughout the world. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and its intellectual property rights in some countries outside the United States and Switzerland can be less extensive than those in the United States and Switzerland. In addition, the laws of some foreign countries do not protect intellectual property to the same extent as laws in the United States and Switzerland. Consequently, NLS may not be able to seek to prevent third parties from practicing its inventions in all countries outside the United States and Switzerland, or from selling or importing products made using its inventions in and into the United States or other jurisdictions. Competitors, for example, may use its technologies in jurisdictions where NLS has not obtained patents to develop their own products and further, may export otherwise infringing products to territories where NLS has patents, but enforcement is not as strong as that in the United States and Switzerland. Many companies have encountered significant problems in protecting and defending intellectual property in foreign jurisdictions. The legal systems of certain countries, particularly China and certain other developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to medical devices and biopharmaceutical and biotechnology products, which could make it difficult for it to stop the infringement of its patents or marketing of competing products in violation of its proprietary rights generally. To date, NLS has not 46 sought to enforce any issued patents in these foreign jurisdictions. Proceedings to enforce its patent rights in foreign jurisdictions could result in substantial costs and divert its efforts and attention from other aspects of its business, could put its patents at risk of being invalidated or interpreted narrowly and its patent applications at risk of not issuing and could provoke third parties to assert claims against us. NLS may not prevail in any lawsuits that NLS initiates and the damages or other remedies awarded, if any, may not be commercially meaningful. The requirements for patentability may differ in certain countries, particularly developing countries. Certain countries in Europe and developing countries, including China and India, have